Clinical Trials
3 trialsNCT03213691 2025-02-05
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03705507 2023-05-11
SeluDex
University of Birmingham
Phase 1/2 Terminated
NCT01278615 2016-02-03
Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated